NCT02025712Unknown2 期
A Phase II Open-label Pilot Study Evaluating the Maintenance Therapy With Exemestane Plus Everolimus After Induction Chemotherapy in Patients With Hormone-receptor Positive Metastatic Breast Cancer
Organisation for Oncology and Translational Research1 个研究点 分布在 1 个国家目标入组 35 人开始时间: 2014年1月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 35
- 试验地点
- 1
- 主要终点
- Progression Free Survival
研究概览
简要总结
The purpose of this study is to determine whether exemestane plus everolimus are effective in the treatment of patients who have achieved disease stabilization after induction chemotherapy for hormone-receptor positive metastatic breast cancer.
详细描述
Postmenopausal women with HR-positive, HER2-negative metastatic breast cancer achieving clinical benefit after the induction chemotherapy for visceral disease with sign(s) and/or symptom(s) will be recruited to receive study the maintenance treatment of everolimus plus exemestane.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Postmenopausal women as defined in the protocol page 9;
- •Histologically and/or cytologically confirmed invasive breast cancer with stage IV disease according to AJCC;
- •Confirmed ER/PR-positive, and HER-2 negative tumor;
- •Disease progression on or following prior endocrine therapy with tamoxifen or non-steroidal aromatase inhibitor, as defined in protocol, prior to standard of care (SOC) induction chemotherapy
- •Patient with documented evidence of visceral disease (including but not limited to hepatic involvement and pulmonary lymphangitic spread of tumor) with sign(s) and/or symptom(s) prior to SOC induction chemotherapy should achieve disease stabilization after the SOC induction chemotherapy, confirmed upon 2 consecutive routine tumor assessments;
- •ECOG performance status ≤ 2 or Karnofsky performance status ≥ 50% prior to the start of study treatment;
- •Adequate organ function prior to the start of study treatment as defined in the protocol;
- •Able to swallow and retain oral medication;
- •Able to give written informed consent;
排除标准
- •Male patient;
- •Metastatic disease limited to the bone or soft tissues only and with no history of other visceral metastases;
- •History of brain or other CNS metastases;
- •Previous treatment with exemestane, unless exemestane was administered in the adjuvant setting and stopped >1 year before metastatic relapse;
- •Untreated with SOC chemotherapy for invasive breast cancer with stage IV disease according to AJCC - or - treated with SOC chemotherapy for invasive breast cancer with stage IV disease according to AJCC without clinical benefit;
- •History of neurological or psychiatric disorders;
- •Any serious cardiovascular diseases in the previous 6 months;
- •Impairment of gastrointestinal function or gastrointestinal disease;
- •Patients with uncontrolled infection;
- •Patients with an active, bleeding diathesis or on oral anti-vitamin K medication (except low dose coumadin defined as 1 mg a day);
- •Chronic treatment with systemic steroids or another immunosuppressive agent;
- •Patients with a pre-existing peripheral neuropathy > grade 1;
- •Patients who are hepatitis B and/or hepatitis C carriers;
- •Known human immunodeficiency virus infection;
- •Prior exposure to mTOR inhibitors;
- •Hypersensitivity to rapamycin or other similar compounds;
- •Patients taking medications known to be inhibitors or inducers of CYP3A4 and/or PgP will not be included in this study;
- •Prior treatment with any investigational agent within the preceding 4 weeks;
- •Other conditions in the judgment of the investigator, would make the patient inappropriate for entry into this study.
- •Other protocol-defined inclusion/exclusion criteria may apply.
研究组 & 干预措施
Exemestane plus Everolimus
Experimental
Exemestane 25 mg daily in combination with Everolimus 10 mg daily until disease progression or intolerable toxicity
干预措施: Exemestane (Drug)
Exemestane plus Everolimus
Experimental
Exemestane 25 mg daily in combination with Everolimus 10 mg daily until disease progression or intolerable toxicity
干预措施: Everolimus (Drug)
结局指标
主要结局
Progression Free Survival
时间窗: Every 8 weeks in the first 24 weeks of treatment and every 12 weeks thereafter, up to 8 months (estimated)
defined as from date of treatment initiation with everolimus plus exemestane to the date of progression or death if no documented disease progression
次要结局
- Clinical benefit rate(Every 8 weeks, up to 8 months (estimated))
- Overall survival(date of treatment initiation with everolimus plus exemestane until the date of death, censored at the last date known alive, whichever came first, assessed up to 32 months)
- Response rate(Every 8 weeks, up to 8 months (estimated))
- Incidence of Adverse Events (AEs)/Serious Adverse Events (SAEs)(Continuous during the study, up to 28 days after the last treatment)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
2 期
Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial CancerAdvanced, Persistent, or Recurrent Endometrial CancerNCT02228681GOG Foundation74
Unknown
3 期
Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast CancerHormone Receptor Positive TumorHuman Epidermal Growth Factor 2 Negative Carcinoma of BreastLocally Advanced Malignant NeoplasmBreast CancerMetastatic Breast CancerNCT02404051Consorzio Oncotech745
已完成
2 期
Exemestane and Cyclophosphamide for Metastatic Breast CancerMetastatic Beast CancerNCT01963481NYU Langone Health23
撤回
2 期
Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In Postmenopausal Women With Hormone Receptor Positive Breast CancerHormone-receptor Positive Breast CancerNCT00615524GlaxoSmithKline
Unknown
2 期
Everolimus trIal for Advanced prememopausaL Breast Cancer PatientsMetastatic Breast CancerNCT02313051Chinese Academy of Medical Sciences200